



FOR IMMEDIATE RELEASE

Immgenuity Inc., Announces the Appointment of Dr. Jessica Robinson-Papp, MD, MS, to its Scientific Advisory Board

Dover, Delaware, April 25, 2023 – Immgenuity, a biotech company focused on developing innovative immunotherapies, announced today that Dr. Jessica Robinson-Papp, MD, MS has joined its Scientific Advisory Board.

Dr. Robinson-Papp is a highly accomplished neurologist and clinical researcher with extensive experience in the development of novel treatments for neurological diseases. She currently serves as the Vice Chair for Clinical Research and Professor of Neurology at the Icahn School of Medicine at Mount Sinai Hospital in New York City. Dr. Robinson-Papp has published over 70 peer-reviewed articles, reviews, editorials and book chapters in top-tier medical journals. She has also served as the principal investigator for numerous clinical trials investigating the safety and efficacy of new treatments for neurological disorders, including multiple sclerosis and peripheral neuropathy.

“We are thrilled to welcome Dr. Robinson-Papp to our Scientific Advisory Board. Her expertise in clinical research and drug development will be invaluable as we continue to advance our innovative therapy for HIV Associated Neurocognitive Disorder (HAND).” said Dr. Sateesh Apte, CEO of Immgenuity.

“I am excited to join the Scientific Advisory Board of Immgenuity and contribute to the development of Immgenuity’s therapeutic platform for addressing HAND. I look forward to working with the Immgenuity team to advance their the development of their promising therapeutic vaccine for HIV”, said Dr. Robinson-Papp.

About Immgenuity, Inc.

Immgenuity, Inc. is a biotechnology company dedicated to developing innovative immunotherapy solutions to improve the lives of patients suffering from HIV. The company's lead product candidate is IMTV014, a novel immunotherapy for HIV and NeuroAIDS, which has shown to be safe in preclinical studies. Immgenuity, Inc. is headquartered in Dover, Delaware and is led by a team of experienced biotech professionals with deep expertise in infectious diseases, immunology, virology, and drug development. For more information, visit <https://immgenuity.com>

About IMTV014

Immgenuity’s immunotherapy, IMTV014 is a genetically modified HIV virus which is unable to block immune signaling like the natural HIV does. By restoring immune signaling, IMTV014 plans to activate the immune system to create a strong, viable immune response against HIV and

likely lead to clearing the virus even from the sanctuary areas where the virus persists despite aggressive anti-HIV drug treatment. IMTV014 will also address various neurological and cardiovascular comorbidities caused by the virus persistence in these anatomical sanctuary areas via prolonged and elevated secretion of inflammatory cytokines. IMTV014 also has application as “salvage therapy” in the multidrug resistant population.

Contact: Media Relations: media@immgenuity.com (302) 321-5844

Forward Looking Statements:

This press release contains “forward-looking statements” within the meaning of federal securities law, including statements concerning the company’s outlook for 2023 and beyond; business strategies and their anticipated results; and similar statements concerning anticipated future events and expectations that are not historical facts. The forward-looking statements in this letter are subject to numerous risks and uncertainties, including the effects of economic conditions; supply and demand changes; competitive conditions in the industry; relationships with clients and distributors; the impact of government regulations; and the availability of capital to finance growth, which could cause actual results to differ materially from those expressed in or implied by the statements herein.